Prognostic Model Based on B Cell Marker Genes for NSCLC Patients Under Neoadjuvant Immunotherapy by Integrated Analysis of Single-cell and Bulk RNA-sequencing Data

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Apr 2

PMID 38563846

Authors

Yang Liu

Fenglong Bie

Guangyu Bai

Qilin Huai

Yuan Li

Xiaowei Chen

Bolun Zhou

Shugeng Gao

Affiliations

Soon will be listed here.

Abstract

Background: Neoadjuvant immunotherapy has evolved as an effective option to treat non-small cell lung cancer (NSCLC). B cells play essential roles in the immune system as well as cancer progression. However, the repertoire of B cells and its association with clinical outcomes remains unclear in NSCLC patients receiving neoadjuvant immunotherapy.

Methods: Single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data for LUAD samples were accessed from the TCGA and GEO databases. LUAD-related B cell marker genes were confirmed based on comprehensive analysis of scRNA-seq data. We then constructed the B cell marker gene signature (BCMGS) and validated it. In addition, we evaluated the association of BCGMS with tumor immune microenvironment (TIME) characteristics. Furthermore, we validated the efficacy of BCGMS in a cohort of NSCLC patients receiving neoadjuvant immunotherapy.

Results: A BCMGS was constructed based on the TCGA cohort and further validated in three independent GSE cohorts. In addition, the BCMGS was proven to be significantly associated with TIME characteristics. Moreover, a relatively higher risk score indicated poor clinical outcomes and a worse immune response among NSCLC patients receiving neoadjuvant immunotherapy.

Conclusions: We constructed an 18-gene prognostic signature derived from B cell marker genes based on scRNA-seq data, which had the potential to predict the prognosis and immune response of NSCLC patients receiving neoadjuvant immunotherapy.

Citing Articles

Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma.

Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T Oncoimmunology. 2025; 14(1):2466308.

PMID: 39963988 PMC: 11845054. DOI: 10.1080/2162402X.2025.2466308.

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.

Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T medRxiv. 2024; .

PMID: 39314968 PMC: 11419212. DOI: 10.1101/2024.09.10.24313432.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Leighl N, Hellmann M, Hui R, Carcereny E, Felip E, Ahn M . Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019; 7(4):347-357. DOI: 10.1016/S2213-2600(18)30500-9. View

Chaft J, Oezkan F, Kris M, Bunn P, Wistuba I, Kwiatkowski D . Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022; 28(10):2155-2161. PMC: 9556329. DOI: 10.1038/s41591-022-01962-5. View

Cascone T, William Jr W, Weissferdt A, Leung C, Lin H, Pataer A . Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021; 27(3):504-514. PMC: 8818318. DOI: 10.1038/s41591-020-01224-2. View

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

Baba Y, Saito Y, Kotetsu Y . Heterogeneous subsets of B-lineage regulatory cells (Breg cells). Int Immunol. 2019; 32(3):155-162. DOI: 10.1093/intimm/dxz068. View

Downs-Canner S, Meier J, Vincent B, Serody J . B Cell Function in the Tumor Microenvironment. Annu Rev Immunol. 2022; 40:169-193. DOI: 10.1146/annurev-immunol-101220-015603. View

Chen H, Ye F, Guo G . Revolutionizing immunology with single-cell RNA sequencing. Cell Mol Immunol. 2019; 16(3):242-249. PMC: 6460502. DOI: 10.1038/s41423-019-0214-4. View

10.

Zhou R, Zhou J, Muhuitijiang B, Zeng X, Tan W . Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer. Aging (Albany NY). 2023; 15(12):5355-5380. PMC: 10333061. DOI: 10.18632/aging.204753. View

11.

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

12.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

13.

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

14.

Li H, Ayer L, Lytton J, Deans J . Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003; 278(43):42427-34. DOI: 10.1074/jbc.M308802200. View

15.

Duan H, Chen B, Wang W, Luo H . Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and experiments. Aging (Albany NY). 2023; 15(5):1445-1474. PMC: 10042700. DOI: 10.18632/aging.204545. View

16.

Sun X, Sun Z, Zhu Z, Guan H, Zhang J, Zhang Y . Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients. PLoS One. 2014; 9(3):e91068. PMC: 3946663. DOI: 10.1371/journal.pone.0091068. View

17.

Wang Y, Li L, Zhao Z, Wang H . Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol. 2013; 11:81. PMC: 3620905. DOI: 10.1186/1477-7819-11-81. View

18.

Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T . TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res. 2016; 35(1):148. PMC: 5028967. DOI: 10.1186/s13046-016-0427-7. View

19.

Miyamoto K, Iwadate M, Yanagisawa Y, Ito E, Imai J, Yamamoto M . Cathepsin L is highly expressed in gastrointestinal stromal tumors. Int J Oncol. 2011; 39(5):1109-15. DOI: 10.3892/ijo.2011.1127. View

20.

Pinto J, Rolfo C, Raez L, Prado A, Araujo J, Bravo L . In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. Sci Rep. 2017; 7(1):1526. PMC: 5431475. DOI: 10.1038/s41598-017-01207-3. View